Huber K - Search Results

1

Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.

Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K, Kurpas D, Niessner A, Schiele F, Semb AG, Sionis A, Claeys MJ, Barrabes J, Montero S, Sinnaeve P, Pedretti R, Catapano A. Krychtiuk KA, et al. Among authors: huber k. Eur Heart J Acute Cardiovasc Care. 2022 Dec 27;11(12):939-949. doi: 10.1093/ehjacc/zuac123. Eur Heart J Acute Cardiovasc Care. 2022. PMID: 36574353 Review.

2

High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease.

Speidl WS, Graf S, Hornykewycz S, Nikfardjam M, Niessner A, Zorn G, Wojta J, Huber K. Speidl WS, et al. Among authors: huber k. Am Heart J. 2002 Sep;144(3):449-55. doi: 10.1067/mhj.2002.124353. Am Heart J. 2002. PMID: 12228781

3

Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease--a 13-year follow-up.

Niessner A, Graf S, Nikfardjam M, Speidl WS, Huber-Beckmann R, Zorn G, Wojta J, Huber K. Niessner A, et al. Among authors: huber beckmann r, huber k. Thromb Haemost. 2003 Aug;90(2):344-50. doi: 10.1160/TH02-10-0185. Thromb Haemost. 2003. PMID: 12888883

4

Pre-existing anticardiolipin antibodies and development of restenosis after coronary balloon angioplasty: predictive value for a complicated course?

Niessner A, Hornykewycz S, Graf S, Nikfardjam M, Speidl WS, Probst P, Zorn G, Maurer G, Wojta J, Huber K. Niessner A, et al. Among authors: huber k. Blood Coagul Fibrinolysis. 2004 Jun;15(4):311-6. doi: 10.1097/00001721-200406000-00004. Blood Coagul Fibrinolysis. 2004. PMID: 15166916

5

An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.

Speidl WS, Zeiner A, Nikfardjam M, Geppert A, Jordanova N, Niessner A, Zorn G, Maurer G, Schreiber W, Wojta J, Huber K. Speidl WS, et al. Among authors: huber k. J Am Coll Cardiol. 2005 Jan 4;45(1):30-4. doi: 10.1016/j.jacc.2004.09.052. J Am Coll Cardiol. 2005. PMID: 15629369 Free article.

6

The adaptive immune system and long-term outcome in patients with stable coronary disease. Predictive value of routine laboratory measurements.

Niessner A, Graf S, Nikfardjam M, Lehr S, Maurer G, Wojta J, Huber K. Niessner A, et al. Among authors: huber k. Thromb Haemost. 2005 Feb;93(2):257-60. doi: 10.1160/TH04-07-0449. Thromb Haemost. 2005. PMID: 15711740

7

Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo.

Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, Goronzy JJ, Weyand CM, Kopp CW, Huber K, Wolzt M, Wojta J. Niessner A, et al. Among authors: huber k. Atherosclerosis. 2006 Dec;189(2):408-13. doi: 10.1016/j.atherosclerosis.2005.12.022. Epub 2006 Jan 26. Atherosclerosis. 2006. PMID: 16443229 Clinical Trial.

8

Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.

Speidl WS, Nikfardjam M, Niessner A, Zeiner A, Jordanova N, Zorn G, Maurer G, Schreiber W, Wojta J, Huber K. Speidl WS, et al. Among authors: huber k. Thromb Res. 2007;119(3):331-6. doi: 10.1016/j.thromres.2006.02.011. Epub 2006 Apr 17. Thromb Res. 2007. PMID: 16616324 Clinical Trial.

9

Premature compared with late onset of coronary artery disease: young patients show a severe defect in fibrinolytic response to venous occlusion.

Speidl WS, Nikfardjam M, Niessner A, Jordanova N, Zorn G, Maurer G, Schreiber W, Wojta J, Huber K. Speidl WS, et al. Among authors: huber k. Blood Coagul Fibrinolysis. 2007 Mar;18(2):165-71. doi: 10.1097/MBC.0b013e328040bf87. Blood Coagul Fibrinolysis. 2007. PMID: 17287634

10

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.

Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Murphy SA, et al. Among authors: huber k. Eur Heart J. 2008 Oct;29(20):2473-9. doi: 10.1093/eurheartj/ehn362. Epub 2008 Aug 5. Eur Heart J. 2008. PMID: 18682445 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,037 results

Search Page